Section Arrow
Quote
LABT.NASDAQ
- Lakewood-Amedex Biotherapeutics Inc
Quotes are at least 15-min delayed:2026/06/11 21:41 EDT
Regular Hours
Last
 0.7228
-0.0359 (-4.73%)
Day High 
0.7699 
Prev. Close
0.7587 
1-M High
3.32 
Volume 
175.91K 
Bid
0.7201
Ask
0.7894
Day Low
0.7154 
Open
0.75 
1-M Low
0.59 
Market Cap 
10.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.67 
20-SMA 0.93 
50-SMA -- 
52-W High 9.82 
52-W Low 0.59 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.33/--
Enterprise Value
10.91M
Balance Sheet
Book Value Per Share
-0.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.013-0.0055-29.73%-- 
TOVXTheriva Biologics Inc0.307+0.0635+26.08%-- 
PPCBPropanc Biopharma Inc.2.43+1.08+80.00%0PE
OTLKOutlook Therapeutics1.1+0.21+23.60%-- 
GERNGeron Corp1.14+0.04+3.64%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.